- 1.
Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RDR. Elevated tumour necrosis factor-alpha (TNF-alfa) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994; 96: 146 – 51.
- 2.
Bos JD, De Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999; 20: 40 – 6.
- 3.
Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000; 59: 1341 – 59.
- 4.
Tan M-H, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of pyoderma gangrenosum and psoriasis associated with Crohns disease with anti-tumor necrosis factor a monoclonal antibody. Arch Dermatol 2001; 137: 930 – 3.
- 5.
Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842 – 7.
- 6.
Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385 – 90.
- 7.
Kirby B, Marsland AM, Carmichael AJ, Griffiths CEM. Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 2001; 26: 27 – 9.
- 8.
Ogilvie ALJ, Antonie C, Dechant C, Manger B, Kalden JR, Schuler G et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alfa clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001; 144: 587 – 9.
- 9.
O’Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alfa antibody (Infliximab) in treating recalcitrant psoriasis. Arch Dermatol 2002; 138: 644 – 8.
- 10.
Fredrikson T, Petterson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978; 157: 238 – 44.
- 11.
Keane J, Gerson S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al. Tuberculosis associated with infliximab, a tumor necrosis factor alfa-neutralizing agent. N Engl J Med 2001; 345: 1098 – 104.
- 12.
Present DH, Rutgeerts P,Targan S, Hanauer SB, Mayer L, Van Hogezand RA et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340: 1398 – 405.
- 13.
Lipsky PE, Van der Heijde DMFM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594 – 602.
- 14.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552 – 63.
- 15.
Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation Patient-Membership Survey. Arch Dermatol 2001; 137: 280 – 4.
- 16.
Krueger JG. The immunologic basis for treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1 – 23.
()